Younger women have a better prognosis among patients with esophageal squamous cell carcinoma after esophagectomy

Su, Xiao Dong; Zhang, Xu; Xie, Hao; Lin, Peng; Rong, Tiehua

doi:10.21037/jtd.2016.03.49

Cited by 13 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we explored the age-dependent relationship between sex and EC survival. Several previous studies have suggested that intrinsic biological sex hormones could be an underlying mechanism that explains the female advantage in cancer incidence and morbidity ( 6 , 8 , 9 , 14 , 22 ). Age 46–55 years is generally used as a surrogate for the perimenopausal period.…”

Section: Discussionmentioning

confidence: 99%

“…However, sex-based disparities in cancer survival are sustained after adjusting for these known risk factors in many cases. In many studies, 55 years of age was generally used as a cut-off age to enter menopause because age is linked to changes in estrogen levels in the life cycle of females ( 5 , 6 ). Mathieu et al found that the annual percentage change in esophageal adenocarcinoma incidence rates for female patients during the same period was negatively correlated with ages 50–54 years and 60–64 years ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Age-Related Sex Disparities in Esophageal Cancer Survival: A Population-Based Study in the United States

Xiang

Xiong

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundThe association between sex and the survival of patients with esophageal cancer (EC) remains controversial. We sought to systematically investigate sex-based disparities in EC survival using the Surveillance, Epidemiology, and End Results (SEER) registry data from the United States.MethodsPatients with EC diagnosed from 2004 to 2015 registered in the SEER database were selected. The association between sex and cancer-specific survival (CSS) was evaluated using survival analysis. The Inverse Probability Weighting (IPW) approach was applied to reduce the observed bias between males and females. Subgroup analyses were used to investigate the robustness of the sex-based disparity and to explore potential interaction effects with other variables.ResultsOverall, 29,312 eligible EC patients were analyzed, of whom 5,781 were females, and 23,531 were males. Females had higher crude CSS compared to males (10-year CSS: 24.5 vs. 21.3%; P < 0.001). Similar results were obtained after adjusting for selection bias using the IPW approach and multivariate regression. Subgroup analyses confirmed the relative robustness of sex as a prognostic factor. However, significant interactions were observed between sex and other variables, such as age, race, tumor grade, histology, and treatment modality. In particular, there was no survival advantage for premenopausal females compared to their male counterparts, but the association between sex and EC survival was prominent in 46–55-year-old patients.ConclusionsFemale EC patients had better long-term survival than males. The association between sex and EC survival vary according to age, race, tumor grade, histology, and treatment modality. Sex-based disparity in EC-specific survival was age-related in the United States population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Age-Related Sex Disparities in Esophageal Cancer Survival: A Population-Based Study in the United States

Xiang

Xiong

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Some investigations also suggested that women with ESCC have a favorable prognosis. Su et al analyzed the prognosis of 674 ESCC patients who underwent surgical resection and found that the 5-year survival rate for females was much higher than that for males (46.8% vs 36.7%, p =0.003) 41. Morita et al .…”

Section: Discussionmentioning

confidence: 99%

Nimotuzumab Plus Paclitaxel and Cisplatin as a 1^st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study

Zhang¹,

Jia²,

Lu³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

The effect of anti-epidermal growth factor receptor targeted treatment in esophageal squamous cell carcinoma (ESCC) is still unclear. We conducted a prospective phase II study of paclitaxel, cisplatin, and nimotuzumab (TPN) as a first-line treatment for unresectable or metastatic ESCC and the objective response rate was 51.8%. Here, we report the long-term follow-up results of the initial trial. Fifty-nine patients were enrolled from Mar 2011 to Apr 2013 and were treated with the TPN regimen. Palliative sequential radiotherapy was given if all tumor lesions were confined to 1-2 radiation fields. Fifty-six patients were eligible for evaluation. After a median follow-up of 32.2months, the median progression-free survival (PFS) and the overall survival (OS) time were 18.1±4.2 months (95% CI: 9.8-26.4) and 26.2±10.0 months (95% CI: 6.6-45.8), respectively, in 29 patients with unresectable local-regional disease, while they were 6.6±0.4 months (95% CI: 5.8-7.5) and 11.5±3.7 months (95% CI: 4.2-18.8), respectively, in 27 patients with metastatic disease. Patients who were male, those with multiple station lymph node metastases, those with visceral metastasis, those who did not response to TPN treatment, and those who did not receive radiotherapy, had a worse OS. In 6 patients with multiple station lymph node metastasis and in 3 patients with recurrent disease and oligo-metastasis (local lymph nodes), TPN with sequential radiation resulted in a mean OS of 17.67±9.50 months and a mean OS of over 40 months, respectively. In conclusion, TPN is effective as a first-line treatment for patients with unresectable and metastatic ESCC. In addition, TPN treatment with sequential radiation might improve survival in patients with limited or oligo lymph node metastases.

show abstract

“…Female sex has been reported to have a better prognosis with esophageal carcinoma. [222324] The influence of younger age and hormones such as estrogen and androgen determine a role in better survival among female patients. [2324]…”

Section: Discussionmentioning

confidence: 99%

Self-Expanding Metallic Stents (SEMS) in inoperable esophageal cancer: A prospective analysis of morbidity and survival outcomes

Sharma

Raina

Sharma

et al. 2019

Indian J Palliat Care

View full text Add to dashboard Cite

Background:Palliative treatment for inoperable esophageal cancers by self-expanding metallic stents (SEMS) overcomes disease-related symptoms, preserves the quality of life, and prolongs survival. The aim of this study was to determine dysphagia relief, complications, and patient survival after SEMS in patients with inoperable esophageal cancer.Methods:This is a hospital-based open cohort study conducted over 9 years between January 1, 2009, and December 31, 2017, from the Sub-Himalayan region of the Indian subcontinent. The last patient was recruited on November 16, 2017 and the minimum of follow-up was either death or survival till December 31, 2017. All the patients attending gastroenterology clinic or admitted in medical wards and fulfilling the definition of inoperable esophageal cancer, subsequently treated with SEMS were included. Data were prospectively gathered on demography, dysphagia scores, morbidity, mortality, and survival outcomes. Follow-ups were done during hospital visits or through a telephonic conversation with the patient and/or caregiver.Results:Of 239 patients, 147 (61.5%) were male and 92 (38.5%) were female. Most of the patients (60.7%) are in the age group of 51–70 years. Squamous cell carcinoma (SCC) was diagnosed in 205 (85.7%) and adenocarcinoma (ADC) in 34 (14.2%). Lower one-third was the most common site of tumor and observed in 125 (52.3%) patients. ADC was diagnosed equally in males and females and the mean age of presentation with ADC was equal to SCC. All the patients had dysphagia score 4, which improved to score 1 after SEMS insertion. Females had better survival than that of males. The difference was found to be statistically significant.Conclusion:SEMS effectively reduced dysphagia in inoperable esophageal cancer. Better survival rates were observed in females than males.

show abstract

Younger women have a better prognosis among patients with esophageal squamous cell carcinoma after esophagectomy

Abstract: Among patients with ESCC after esophagectomy, women younger than age 55 years attained a favorable prognosis.

Cited by 13 publications

References 23 publications

Age-Related Sex Disparities in Esophageal Cancer Survival: A Population-Based Study in the United States

Age-Related Sex Disparities in Esophageal Cancer Survival: A Population-Based Study in the United States

Nimotuzumab Plus Paclitaxel and Cisplatin as a 1^st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study

Self-Expanding Metallic Stents (SEMS) in inoperable esophageal cancer: A prospective analysis of morbidity and survival outcomes

Contact Info

Product

Resources

About

Younger women have a better prognosis among patients with esophageal squamous cell carcinoma after esophagectomy

Abstract: Among patients with ESCC after esophagectomy, women younger than age 55 years attained a favorable prognosis.

Cited by 13 publications

References 23 publications

Age-Related Sex Disparities in Esophageal Cancer Survival: A Population-Based Study in the United States

Age-Related Sex Disparities in Esophageal Cancer Survival: A Population-Based Study in the United States

Nimotuzumab Plus Paclitaxel and Cisplatin as a 1st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study

Self-Expanding Metallic Stents (SEMS) in inoperable esophageal cancer: A prospective analysis of morbidity and survival outcomes

Contact Info

Product

Resources

About

Nimotuzumab Plus Paclitaxel and Cisplatin as a 1^st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study